Reports that a small subset of tumor cells initiate and sustain tumor growth, are resistant to radiation and drugs, and bear specific markers have led to an explosion of cancer stem cell research. These reports imply that the evaluation of therapeutic response by changes in tumor volume is misleading, as volume changes reflect the response of the sensitive rather than the resistant tumorigenic cell population. The reports further suggest that the marker-based selection of the tumor cell population will facilitate the development of radiation treatment schedules, sensitizers, and drugs that specifically target the resistant tumorigenic cells that give rise to treatment failure.
Introduction
Reports that a small percentage of tumor cells are tumorigenic, bear specific markers, and are treatment resistant have stimulated and sustained cancer stem cell research for the past dozen years. The reports suggest that the assessment of treatment efficacy by changes in tumor volume is misleading, as volume changes reflect the response of the predominant sensitive non-stem tumor cell population rather than the resistant tumor initiating and sustaining population. The reports also form the basis for designing treatments that specifically target the marker-bearing tumor subpopulation. This article presents evidence that contests the notion that cancer stem cell markers identify all tumorigenic cells and that the marker identified population is resistant to radiation. Specifically, studies indicate that (i) recurrent tumors are equally or more radiocurable than parental nonirradiated tumors, (ii) cells from tumors surviving large subcurative doses of radiation are not more radioresistant than cells from unirradiated tumors, and (iii) the slopes of radiation dose versus percent tumor cure curves, do not differ from the slopes of radiation dose versus percent survival of nonselected in vitro colony-forming tumor cells. Furthermore, studies show that the number of tumor-initiating cells per tumor, in combination with the in vitro measured radiation sensitivity of nonselected colony-forming tumor cells from the same tumor, predicts the radiation control dose of isografted murine and xenografted human tumors.
Not All Tumor Cells Are Tumorigenic, and the Fraction That Is, Is Dynamic
In 1973, Hewitt and colleagues reported that the number of injected cells from five spontaneous murine tumors that was needed to achieve a 50% successful transplantation take rate (TD 50 ), in recipient syngeneic mice, ranged from 21 cells to 24,000 cells (1) . That is, the fraction of injected cells that was tumor initiating ranged from approximately 1 in 21 to 1 in 24,000. Additionally, and similar to previously reported in vitro studies (2) , the study demonstrated that the expression of a cell's tumorigenic potential was influenced by its microenvironment. Specifically, when unirradiated tumor cells were mixed with lethally irradiated tumor cells immediately prior to injection, the number of unirradiated cells needed to initiate tumors decreased in 4 of the 5 tumor types. For example, the TD 50 decreased from 190 cells to 14 cells, and for another, from 6,900 cells to 4.4 cells. Similar to the impact of lethally irradiated cells, Matrigel, a matrix-like protein substance containing various growth factors, also reduces the number of injected tumor cells needed to initiate tumors in immunodeficient mice (3, 4) . Thus, while only a fraction of tumor cells appear to be capable of initiating and sustaining tumor growth, the expression of the tumorigenic potential is dependent on microenvironmental factors.
The Size of the Tumor-Initiating Cell Fraction Impacts Radiocurability
Hill and Milas evaluated the relationship between the fraction of tumor cells that were tumor initiating and the tumor's radiocurability (5) . A significant correlation was observed between the tumorigenic fraction of 25 spontaneous murine tumors and the radiation dose required to achieve permanent local tumor control (P ¼ 0.01). Additionally, the relationship between the fraction of injected tumor cells capable of initiating tumors and the fraction of the same cells that formed colonies in vitro was examined in a subset of 12 spontaneous mammary carcinomas. Although the fraction of cells that formed colonies was larger than the fraction that initiated tumors, the two values significantly correlated (P ¼ 0.01). The study thus demonstrated a significant relationship between the fraction of tumor cells capable of forming tumors in vivo, the fraction that formed colonies in vitro, and the tumor control dose. These data generally support the cancer stem cell hypothesis.
Do Cancer Stem Cell Markers Identify All and Only Cancer Stem Cells?
Commonly cited cancer stem cell markers include cell-surface proteins (e.g., CD24, CD44, and CD133), cells exhibiting an enhanced capacity for exclusion of dyes such as Hoechst 33342, and cells exhibiting an elevated activity of the enzyme aldehyde dehydrogenase (ALDH). A mechanistic relationship between the various markers and cancer stem cell characteristics such as indefinite self-renewal and radiation sensitivity remains under investigation but is not well established (6) (7) (8) .
In seminal studies, Al-Hajj and colleagues reported that greater than 1,000 nonmarker-selected cells from xenografts were required for the initiation of orthotopic tumors in nonobese diabetic SCID (NOD/SCID) mice, whereas as few as 100 CD profile. Tumors could be initiated by the injection of 3,000 mammosphere cells versus greater than 100,000 unselected cells from the MCF7 mammary tumor cell line. In contrast to these results, in estrogen receptor-negative human breast cancers, Meyer and colleagues (11) (12) . Concurrent with these breast tumor studies, it was reported that as pertained to normal brain, a small fraction of cells from brain tumors cultured in low-attachment culture dishes without serum but supplemented with growth factors gave rise to the growth of cell spheres (13) (14) (15) (16) To summarize, the percentage of tumorigenic cells in a marker selected population is generally substantially higher than in a nonselected or marker-negative population. Nevertheless, the majority of marker selected cells are not tumorigenic, and marker-negative cells may also exhibit tumorigenicity. Additionally, cells from different tumors of the same tumor type, although bearing the same marker or marker combination, are not equally tumorigenic. References (6, 7, 20) further examine the distribution of proposed cancer stem cell markers in tumors and normal tissues as well as marker specificity and the tumorigenicity of marker-bearing cells.
Are Tumors and Tumor Cells Surviving Large Doses of Radiation Radioresistant?
The small percentage of marker-bearing tumorigenic cells within a much larger population of marker-bearing nontumorigenic cells confounds an assessment of the radiation sensitivity of the tumorigenic cells based on marker expression. This pertains regardless of the response metric. While an increase in the fraction of cells exhibiting a marker following irradiation may be indicative of greater resistance of the marker-bearing cells, the assay requires the passage of several hours to days between radiation and marker quantification, to clear the radiation sterilized cells from the analyzed population. The findings are also contingent on the absence of radiation-induced reprogramming of marker-negative tumor cells into marker-positive cells, as has been reported previously (21, 22) . In short, increased marker expression following irradiation is not equivalent to an evaluation of the radiation sensitivity of demonstrably tumorigenic cells that survive irradiation.
Suit (23) exposed isotransplants of a spontaneous murine mammary tumor to various dose levels. In tumors receiving a TCD 95 dose (the dose that on average achieved permanent local control of 95% of treated tumors), a recurrent tumor was excised and isotransplanted into syngeneic mice. The TCD 50 of the recurrent transplanted tumor was lower than pertained to unirradiated tumors, i.e., 51.3 versus 59.9 Gy. Ando and colleagues (24) reported that the TCD 50 of a recurrent isotransplanted spontaneous fibrosarcoma was substantially lower than the parental tumor, i.e., 58.0 versus 78.9 Gy. The tumors' stem cell fractions, resolved by the TD 50 transplantation assay, were similar in the nonirradiated control and recurrent tumors. Majima and colleagues (25) also found that the radiosensitivity of tumor clones, isolated from recurrent murine tumors following large subcurative doses of radiation, were not more radioresistant than clones from unirradiated tumors. The enhanced radiocurability of heavily irradiated recurrent tumors is consistent with earlier in vitro studies first reported by Sinclair (26) . An increasing fraction of cells surviving increasingly large single radiation doses exhibited increasing radiosensitivity, i.e., "heritable non-lethal damage." Studies reporting a similar or greater sensitivity of tumors and cells surviving large single-fraction irradiation do not preclude the possibility that multiple smaller doses of radiation administered over days to weeks may select for a preexisting relatively resistant tumorigenic subpopulation. This possibility warrants investigation; however, it is informative to note that Yaromina and colleagues reported a highly significant correlation between the single-dose TCD 50 The colony formation assay has long been considered the gold-standard in vitro assay for assessing the intrinsic radiosensitivity of tumor cells. Few, if any, of the thousands of published in vitro radiation survival curves exhibit a decrease in slope indicative of a small resistant subpopulation of cells at high radiation doses. In addition to in vitro colony formation studies, the TCD 50 assay provides a powerful quantitative tool for directly assessing the sensitivity of tumorigenic cells in their in situ environment. Rofstad and colleagues exposed human melanoma xenografts to a range of doses and measured the slope of a curve fit to percent tumor cure versus dose. The slopes of the curves did not differ from the slopes of curves fit to percent surviving fraction of cells from the same tumors that were exposed to various doses of radiation in vivo, and then plated for in vitro colony formation (42) . Baumann and colleagues examined the in situ cell sensitivity of the human squamous cell carcinoma FaDu by evaluation of the TCD 50 of tumors of increasing size and number of colony-forming cells (43) . After adjusting for differences in the sensitivity of cells irradiated under oxygenated conditions in vitro, and hypoxic conditions in vivo, their study showed that the slope of a curve fit to the dose to achieve 50% tumor control versus clonogens per tumor did not differ from the survival curve slope of FaDu cells irradiated in vitro. Interrogation and validation of the equivalent sensitivity of colony-forming tumor cells and the in situ sensitivity of tumorigenic cells is illustrated in Fig. 1 . Studies by both Rofstad and colleagues and Baumann and colleagues demonstrated that the radiation sensitivity of colony-forming tumor cells and cells that lead to treatment failure if not sterilized did not differ. (44) . To assess this possibility, the tumorigenic fraction of four spontaneous murine tumors in syngeneic mice and two human tumors in nude mice was evaluated by the TD 50 assay. These data were combined with the in vitro radiation sensitivity of the unsorted tumor cells from the tumors, to predict the tumors' 50% tumor control doses. The number of tumor-initiating cells per tumor and their intrinsic radiosensitivity predicted the measured 50% tumor control doses with a rank-order correlation coefficient of 1.0, P ¼ < 0.01. Adjusting for the oxygen-dependent difference in radiosensitivity between uniformly oxygenated cells in vitro and uniformly hypoxic tumors, the average difference between the predicted and measured TCD 50 values was approximately 3 Gy (44). These results provide evidence that elimination of the tumorigenic cell fraction is required for the successful radiotherapy of cancer, and these tumorigenic cells are not more resistant than the bulk colony-forming tumor cells.
Summary

*
The size of the tumorigenic cell fraction is tumor specific and is significantly influenced by the tumor cells' microenvironment. These results indicate that colony-forming tumor cells constitute an appropriate cell population for targeting, enhancing, and quantifying the radiation sensitivity of tumor cells, which give rise to treatment failure if not sterilized. They caution against overreliance on "markers" for the identification of the tumorigenic cell population and its radiosensitivity.
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